WITHDRAWN:New PET imaging agents in the management of solid cancers.
Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.Current opinion in oncology (Impact Factor: 4.47). 03/2012; DOI: 10.1097/CCO.0b013e3283528116
PURPOSE OF REVIEW: PET-computed tomography (PET-CT) imaging has been increasingly studied and used in clinical practice during the last decades. This imaging technique offers a holistic approach of cancer diagnosis as it can integrate structural, functional, metabolic, and even molecular information of tumours. The technique offers three-dimensional, high resolution, whole body and quantitative imaging. The most commonly used tracer at present is the glucose analogue F-fluoro-2-deoxy-D-glucose (FDG). FDG PET and FDG PET/CT have a well established role in the management of most cancer patients, but they also have some limitations. For the last 20 years, a growing number of non-FDG PET tracers have been used in oncology research and some of these become more and more used in clinical practice. RECENT FINDINGS: Many 'new' non-FDG PET tracers were investigated largely in preclinical models, but in the last years, some of these tracers were used in clinical settings for noninvasive assessment of different biologic functions in cancer cells. This unique information should contribute to make tailored cancer therapy a reality. SUMMARY: This review summarizes the most representative PET tracers other than FDG, used in clinical oncology applications for solid tumours reported during the period 2010-2011.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.